Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.9375 per EA under NDC 67877062460. Its NADAC has been published 44 times since Dec 3, 2025.
FDA first approved this application on Mar 11, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
110 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877062460
Classification
Generic
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208040FDA Approved
3/11/2020
TE Code
AB
On Market Since
9/12/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 44 times since Dec 3, 2025, and over the history we have for it it has declined 41.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9375 per EA |
|---|---|
| All-time high | $1.6053 (Dec 10, 2025) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.6053 |
| 52-week low | $0.9196 |
| Median price | $0.9737 |
| Average price | $1.0762 |
| Largest weekly change | -12.4% (Dec 17, 2025) |
| Weeks tracked | 44 |
| Tracking since | Dec 3, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dabigatran Etexilate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Direct Thrombin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Ascend Laboratories, LLC, is $0.9375 per EA (NDC 67877062460), effective Sep 30, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 41.6%. It has been tracked across 44 weekly CMS publications since Dec 3, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Dec 3, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.6053 (Dec 10, 2025), with a median of $0.9737 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 67877062460) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.